Download Champions' latest AACR 2025 Poster
Establishment of an orthotopic intracranial luciferase-labelled patient-derived xenograft of glioblastoma in an immunocompromisedmouse model
Glioblastoma (GBM), the most common primary brain tumor, remains one of the deadliest cancers due to its aggressive nature and lack of effective treatments. One of the main challenges in developing therapies is the absence of preclinical models that faithfully replicate the tumor’s intracranial microenvironment and clinical progression. Conventional subcutaneous models fail to capture this complexity, limiting translational potential.
Champions Oncology developed an orthotopic glioblastoma model by implanting luciferase-labeled U87 and patient-derived glioblastoma cells into the cortices of immunocompromised mice using a stereotaxic apparatus. This approach enables non-invasive, longitudinal monitoring of tumor growth via bioluminescent imaging.
Champions Oncology developed an orthotopic glioblastoma model by implanting luciferase-labeled U87 and patient-derived glioblastoma cells into the cortices of immunocompromised mice using a stereotaxic apparatus. This approach enables non-invasive, longitudinal monitoring of tumor growth via bioluminescent imaging.
- Luciferase labeling was validated ex vivo, confirming a strong correlation between luminescence and cell number for U87 and patient-derived glioblastoma lines.
- Orthotopic implantation led to consistent, exponential tumor growth with minimal variability across replicates, mimicking clinical progression and demonstrating successful model establishment.
- This intracranial model provides a relevant microenvironment for tumor development, making it a valuable platform for testing glioblastoma therapies and advancing preclinical drug screening in a clinically relevant setting.
Download the Poster